Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Search
Drug Profile

Obexelimab - Zenas Biopharma

Alternative Names: AMG 729; Humanised Fc-engineered monoclonal antibody against CD19 - Xencor; XmAb® 5871

Latest Information Update: 12 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xencor
  • Developer Xencor; Zenas BioPharma
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; Fc gamma receptor IIB antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autoimmune disorders
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Autoimmune haemolytic anaemia; Immunoglobulin G4-related disease; Multiple sclerosis
  • Phase II Rheumatoid arthritis; Systemic lupus erythematosus
  • No development reported Autoimmune disorders

Most Recent Events

  • 02 Feb 2025 Phase-II clinical trials in Multiple sclerosis (Treatment-experienced) in Austria, Belgium, China, Croatia, Czech Republic, Denmark, Greece, Italy, Poland, Spain, United Kingdom (SC) (NCT06564311)
  • 07 Jan 2025 Phase-II clinical trials in Systemic lupus erythematosus (Treatment-experienced) in Bulgaria, China, Germany, Greece, Japan, Italy, Poland, Portugal, Romania, Spain, Taiwan (SC) (NCT0655916)
  • 07 Dec 2024 Pharmacodynamics data from preclinical trial in Autoimmune haemolytic anaemia presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days

New Timelines Chart

We recently added a timeline chart on all drug profiles. You can choose the indication from the drop down menu near the top. The chart will show the time the drug spent in different phases as it progressed through development for that indication. The end result is a Gantt style chart illustrating how long the drug took in each phase. This new chart takes advantage of our longitudinal pipeline data which we have stored every month since 2004. Please use the thumbs up/down buttons to let us know your opinion about this new feature.